Literature DB >> 16782716

Substrate modification combined with pulmonary vein isolation improves outcome of catheter ablation in patients with persistent atrial fibrillation: a prospective randomized comparison.

Stephan Willems1, Hanno Klemm, Thomas Rostock, Benedikt Brandstrup, Rodolfo Ventura, Daniel Steven, Tim Risius, Boris Lutomsky, Thomas Meinertz.   

Abstract

AIMS: To investigate the effectiveness of additional substrate modification (SM) by left atrial (LA) linear lesions as compared with pulmonary vein isolation (PVI) alone in patients with persistent atrial fibrillation (AF) in a prospective randomized study. Percutaneous PVI has evolved as an accepted treatment for paroxysmal AF but seemed to be less effective in patients with persistent AF. The benefit of PVI alone and additional linear lesions has not been validated in a randomized study so far. METHODS AND
RESULTS: Sixty-two patients with persistent AF (median duration 7, range 1-18 months) were randomly assigned to either PVI alone (n = 30) or additional SM (n =32) consisting of a roof line connecting both left superior and right superior PV and LA isthmus ablation between left inferior PV and mitral annulus. Procedures including SM were performed using a three-dimensional mapping system (EnSite NavX, St Jude Medical, St Paul, MN, USA). Anti-arrhythmic drugs were discontinued within 8 weeks after ablation in both groups. Follow-up included daily trans-telephonic ECG transmitted irrespective of the patient's symptoms. PVI was successful in 98% of all targeted veins in both groups. Additional SM did not increase fluoroscopy time (72.1+/-18.7 vs. 72.9+/-17.3 min, P=0.92) because of the use of three-dimensional navigation in the PVI+SM group. AF recurrences within the first 4 weeks following ablation were more common after PVI alone (77%) than additional SM (44%, P=0.002). After a follow-up time of 487 (429-570) days, only 20% of patients undergoing stand alone PVI remained in sinus rhythm when compared with 69% following PVI combined with SM (P=0.0001). Two patients assigned to PVI+SM experienced procedure-related complications (cardiac tamponade and minor stroke) which resolved without sequelae.
CONCLUSION: PVI alone is insufficient in the treatment of persistent AF. However, additional left linear lesions increase the success rate significantly. Early AF-relapses are associated with a negative outcome after PVI alone but not following additional SM.

Entities:  

Mesh:

Year:  2006        PMID: 16782716     DOI: 10.1093/eurheartj/ehl093

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  57 in total

Review 1.  [Current strategies in the treatment of atrial fibrillation].

Authors:  Imke Drewitz; Thomas Rostock; Boris Hoffmann; Daniel Steven; Helge Servatius; Thomas Meinertz; Stephan Willems
Journal:  Med Klin (Munich)       Date:  2008-11-15

Review 2.  Approaches to Catheter Ablation of Nonparoxysmal Atrial Fibrillation.

Authors:  Jackson J Liang; Daniele Muser; Pasquale Santangeli
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

3.  Apnea-hypopnea index as a predictor of atrial fibrillation recurrence following initial pulmonary vein isolation: usefulness of type-3 portable monitor for sleep-disordered breathing.

Authors:  Hiroshi Kawakami; Takayuki Nagai; Akira Fujii; Teruyoshi Uetani; Kazuhisa Nishimura; Katsuji Inoue; Jun Suzuki; Yasunori Oka; Takafumi Okura; Jitsuo Higaki; Akiyoshi Ogimoto; Shuntaro Ikeda
Journal:  J Interv Card Electrophysiol       Date:  2016-06-08       Impact factor: 1.900

4.  Electrogram characteristics of the coronary sinus in cases requiring epicardial ablation within the coronary sinus for creating a conduction block at the left lateral mitral isthmus.

Authors:  Daisuke Sato; Hiroki Mani; Yu Makihara; Hiroki Kitajima; Yuji Nishikawa; Seno Keitaro; Yeong-Hwa Chun
Journal:  J Interv Card Electrophysiol       Date:  2018-06-27       Impact factor: 1.900

5.  Catheter ablation of persistent atrial fibrillation: The importance of substrate modification.

Authors:  Konstantinos P Letsas; Michael Efremidis; Nikolaos P Sgouros; Konstantinos Vlachos; Dimitrios Asvestas; Antonios Sideris
Journal:  World J Cardiol       Date:  2015-03-26

6.  Comparative effectiveness of catheter ablation strategies for rhythm control in patients with atrial fibrillation: a meta-analysis.

Authors:  Nazila Assasi; Feng Xie; Gord Blackhouse; Kathryn Gaebel; Diana Robertson; Rob Hopkins; Jeff S Healey; Ron Goeree
Journal:  J Interv Card Electrophysiol       Date:  2012-10-03       Impact factor: 1.900

7.  Initial experience of sequential surgical epicardial-catheter endocardial ablation for persistent and long-standing persistent atrial fibrillation with long-term follow-up.

Authors:  Srijoy Mahapatra; Damien J LaPar; Sandeep Kamath; Jason Payne; Kenneth C Bilchick; James M Mangrum; Gorav Ailawadi
Journal:  Ann Thorac Surg       Date:  2011-06       Impact factor: 4.330

8.  Long-term outcomes of adjunctive complex fractionated electrogram ablation to pulmonary vein isolation as treatment for non-paroxysmal atrial fibrillation.

Authors:  Alessandro De Bortoli; Ole-Jørgen Ohm; Per Ivar Hoff; Li-Zhi Sun; Peter Schuster; Eivind Solheim; Jian Chen
Journal:  J Interv Card Electrophysiol       Date:  2013-07-07       Impact factor: 1.900

9.  Atrial tachycardias arising from ablation of atrial fibrillation: a proarrhythmic bump or an antiarrhythmic turn?

Authors:  Ashok J Shah; Amir Jadidi; Xingpeng Liu; Shinsuke Miyazaki; Andrei Forclaz; Isabelle Nault; Lena Rivard; Nick Linton; Olivier Xhaet; Nicolas Derval; Frederic Sacher; Pierre Bordachar; Philippe Ritter; Meleze Hocini; Pierre Jais; Michel Haissaguerre
Journal:  Cardiol Res Pract       Date:  2010-04-07       Impact factor: 1.866

10.  The optimal setting of complex fractionated atrial electrogram software in substrate ablation for atrial fibrillation.

Authors:  Fuminori Namino; Yasuhisa Iriki; Ryuichi Maenosono; Hitoshi Ichiki; Hideki Okui; Akino Yoshimura; Naoya Oketani; Masakaze Matsushita; Mitsuru Ohishi; Teruto Hashiguchi
Journal:  J Arrhythm       Date:  2014-06-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.